Late drug-resistance in mild MTLE: Can it be influenced by preexisting white matter alterations?

Angelo Labate1,2, Maria Eugenia Caligiuri2, Francesco Fortunato1

  • 1Institute of Neurology, University Magna Graecia, Catanzaro, Italy.

Epilepsia
|April 21, 2020
PubMed
Abstract

Insights

Early white matter abnormalities in mild mesial temporal lobe epilepsy (mMTLE) predict future drug-resistance. These pre-existing changes may stem from genetic factors, not seizure activity or treatments.

Area of Science:

  • Neurology
  • Neuroimaging
  • Epilepsy Pathophysiology

Background:

  • Mild mesial temporal lobe epilepsy (mMTLE) is a drug-responsive epilepsy ideal for studying early disease markers.
  • Identifying predictors of drug-resistance is crucial for long-term patient outcomes.

Purpose of the Study:

  • To detect early structural brain changes associated with the future development of drug-resistance in mMTLE.
  • To investigate potential prognostic markers for epilepsy treatment response.

Main Methods:

  • Longitudinal MRI (1.5T and 3T) including diffusion-weighted imaging was used in 55 mMTLE patients over 12 years.
  • Voxel-based morphometry and Freesurfer analysis assessed white matter volume and integrity.
  • Statistical analyses controlled for clinical and demographic factors, including hippocampal sclerosis.

Main Results:

  • Patients who later developed drug-resistance (refractory MTLE [rMTLE]) showed pre-existing white matter reductions in specific tracts (arcuate fasciculi, corticospinal tracts, cingulum, inferior longitudinal fasciculus).
  • At follow-up, rMTLE patients exhibited decreased fractional anisotropy in the corpus callosum and superior longitudinal fasciculi.
  • These white matter abnormalities were present before the onset of drug-resistance and independent of hippocampal sclerosis.

Conclusions:

  • Pre-existing white matter abnormalities in temporal and extratemporal regions are associated with the future development of drug-resistance in mMTLE.
  • These findings suggest a potential genetic predisposition rather than secondary damage from seizures or treatments.
  • Early neuroimaging markers could aid in predicting epilepsy treatment outcomes.

Related Concept Videos

Long-term Depression01:05

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation01:25

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Long-term Depression01:03

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...